Design Therapeutics, Inc.
DSGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807120
No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Design Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 83 | 96 | +13 |
| Shares | 40.4M | 38.7M | −1.68M (−4.2%) |
| Value | $414.2M | $223.3M | −$190.9M (−46.1%) |
New holders (32)
Institutions that held Design Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (19)
Institutions that held Design Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| EcoR1 Capital, LLC | 884,903 | $9.08M |
| Rafferty Asset Management, LLC | 243,585 | $2.50M |
| Ghost Tree Capital, LLC | 82,853 | $850.0K |
| Acadian Asset Management LLC | 57,957 | $594.0K |
| Silverarc Capital Management, LLC | 57,025 | $585.1K |
| Bellevue Group AG | 34,881 | $357.9K |
| Virtus Investment Advisers, Inc. | 14,400 | $147.7K |
| E Fund Management Co., Ltd. | 12,523 | $128.0K |
| Envestnet Asset Management Inc | 12,236 | $125.5K |
| Ikarian Capital, LLC | 11,568 | $118.7K |
| Walleye Capital LLC | 10,703 | $109.8K |
| Dark Forest Capital Management LP | 1,669 | $17.1K |
| High Net Worth Advisory Group LLC | 1,000 | $10.3K |
| Group One Trading, L.P. | 500 | $5.13K |
| Allspring Global Investments Holdings, LLC | 201 | $2.06K |
| TCI Wealth Advisors, Inc. | 84 | $862 |
| Credit Suisse AG | 1 | $10 |
| CWM, LLC | 24 | $0 |
| Rockefeller Capital Management L.P. | 61 | $0 |